The prediction model allows for the prioritization of ACTB for individuals with the common comorbidities of sensorineural hearing loss and arthropathy/arthritis with risk of AD (where the SPOKE informed connection linking sensorineural hearing loss, arthropathy, arthritis and AD all together through ACTB has not been previously implicated in literature). This evidence concerns the gene ACTB and arthritic joint disease.